Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M19,141Revenue $M751Net Margin (%)-17.8Z-Score12.2
Enterprise Value $M18,851EPS $-0.9Operating Margin %-12.4F-Score4
P/E(ttm))0Cash Flow Per Share $-0.1Pre-tax Margin (%)-16.6Higher ROA y-yY
Price/Book11.610-y EBITDA Growth Rate %0Quick Ratio5.2Cash flow > EarningsY
Price/Sales23.45-y EBITDA Growth Rate %0Current Ratio6.1Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-5.7Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-9.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M159ROI % (ttm)-9.2Gross Margin Increase y-yY

Gurus Latest Trades with BMRN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMRNJoel Greenblatt 2014-12-31 Sold Out $67.27 - $94.19
($83.42)
$ 120.2831%Sold Out0
BMRNJoel Greenblatt 2014-09-30 Buy $55.78 - $73
($65.82)
$ 120.2845%New holding3,885
BMRNMeridian Funds 2013-06-30 Sold Out -0.09%$54.72 - $70.3
($62.32)
$ 120.2848%Sold Out0
BMRNMeridian Funds 2013-03-31 Reduce-0.17%$49.2 - $62.39
($56.51)
$ 120.2853%Reduce -69.03%40,700
BMRNMeridian Funds 2012-12-31 Reduce-0.3%$36.78 - $50.17
($45.59)
$ 120.2862%Reduce -60.99%131,400
BMRNGeorge Soros 2012-06-30 Sold Out -0.15%$32.53 - $38.87
($36.01)
$ 120.2870%Sold Out0
BMRNGeorge Soros 2012-03-31 Add0.11%$33.68 - $38.34
($32.99)
$ 120.2873%Add 300.00%300,000
BMRNGeorge Soros 2011-12-31 Reduce-0.05%$30.07 - $35.38
($32.81)
$ 120.2873%Reduce -57.14%75,000
BMRNGeorge Soros 2011-06-30 Add0.07%$24.93 - $28.455
($26.32)
$ 120.2878%Add 862.36%191,510
BMRNMeridian Funds 2011-03-31 Reduce-0.28%$23.46 - $28.29
($25.46)
$ 120.2879%Reduce -51.54%348,800
BMRNGeorge Soros 2011-03-31 Buy 0.01%$23.46 - $28.29
($25.46)
$ 120.2879%New holding19,900
BMRNGeorge Soros 2010-09-30 Sold Out -0.02%$18.24 - $23.09
($20.93)
$ 120.2883%Sold Out0
BMRNMeridian Funds 2010-03-31 Add0.13%$18.75 - $23.81
($20.92)
$ 120.2883%Add 20.83%795,900
BMRNGeorge Soros 2010-03-31 Add$18.75 - $23.81
($20.92)
$ 120.2883%Add 35.87%30,300
BMRNGeorge Soros 2009-12-31 Buy 0.01%$15.49 - $18.98
($17.17)
$ 120.2886%New holding22,300
BMRNMeridian Funds 2009-09-30 Buy 0.53%$13.86 - $18.33
($15.84)
$ 120.2887%New holding658,700
BMRNBill Gates 2009-06-30 Sold Out -0.02%$11.92 - $15.94
($13.79)
$ 120.2889%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMRN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BMRN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BIENAIME JEAN JACQUESCEO 2015-04-01Sell26,052$120.53-0.21view
BIENAIME JEAN JACQUESCEO 2015-03-20Sell1,000$126.4-4.84view
BIENAIME JEAN JACQUESCEO 2015-03-17Sell2,000$124.17-3.13view
FUCHS HENRY JEVP, Chief Medical Officer 2015-03-16Sell41,315$123.57-2.66view
Davis George EricSVP, General Counsel 2015-03-13Sell15,000$120.87-0.49view
BIENAIME JEAN JACQUESCEO 2015-03-10Sell21,021$112.397.02view
BIENAIME JEAN JACQUESCEO 2015-03-05Sell10,000$113.75.79view
BAFFI ROBERTEVP, Technical Operations 2015-03-05Sell14,051$116.373.36view
BIENAIME JEAN JACQUESCEO 2015-03-04Sell13,916$107.9211.45view
Mueller BrianVP, Corporate Controller 2015-03-03Sell7,000$109.469.88view

Press Releases about BMRN :

    Quarterly/Annual Reports about BMRN:

    News about BMRN:

    Articles On GuruFocus.com
    J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 
    WEEKLY CFO SELLS HIGHLIGHT: VVUS, DIS, SNPS, TXRH, BMRN Mar 04 2012 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
    BioMarin Pharmaceutical Inc. Reports Operating Results (10-K) Feb 24 2011 
    BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 13 2010 
    BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 2,000 Shares Dec 13 2010 
    BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 07 2010 


    More From Other Websites
    Catalyst Pharma Competitor Surprises With Positive Orphan Disease Drug Study Results Apr 24 2015
    BioMarin Presents Data on Duchenne Muscular Dystrophy at the 67th American Academy of Neurology... Apr 23 2015
    4:55 pm Biomarin Pharm announces natural history study of patients with Duchenne muscular dystrophy... Apr 23 2015
    BioMarin Presents Data on Duchenne Muscular Dystrophy at the 67th American Academy of Neurology... Apr 23 2015
    Santhera -- A Duchenne Drug With Positive Study Results That Few Know About Apr 23 2015
    BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Apr 21 2015
    BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Apr 21 2015
    Should Gilead Sciences Buy Vertex? Bernstein Says Yes, Maxim Says No Apr 21 2015
    BioMarin to Host First Quarter 2015 Financial Results Conference Call and Webcast on Thursday, April... Apr 14 2015
    BioMarin to Host First Quarter 2015 Financial Results Conference Call and Webcast on Thursday, April... Apr 14 2015
    Endo International plc (ENDP), BioMarin Pharmaceutical Inc. (BMRN): Visium Picks Returned 13% but... Apr 10 2015
    The Oprahs Of Biotech: People Who Can Go By First Name Only Apr 10 2015
    Billionaire John Griffin’s Five Picks That Killed the Market This Quarter Apr 09 2015
    BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K/A, Financial Statements and Exhibits Apr 03 2015
    Retrophin Hits High On Bullish Initiation Report Apr 02 2015
    Sarepta CEO Exits, Eteplirsen Regulatory Filing on Track - Analyst Blog Apr 01 2015
    Sudden Exit of Sarepta CEO Fuels Speculation That Soured FDA Relationship Is to Blame Mar 31 2015
    Biotech's next buzz: Gene therapy? Mar 31 2015
    How bubbles are blown: Biotech edition Mar 31 2015
    Cramer tackles a tough tweet Mar 30 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK